

February 18, 2020

CompanyAnicom Holdings, Inc.Representative DirectorNobuaki Komori(Securities Code: 8715 TSE 1st section)Inquiries toTatsuhiko KameiManaging Executive Officer

## Notice of the status of our activities, January 2020

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.


Notice of the status of	our activities	2019 (From Anril	1, 2019 to March 31, 2020)
Notice of the status of	our activities,		1, 2019 to March 31, 2020

	April	May	June	July	August	September
Net premiums written	<b>3,062</b> JPYmn	<b>3,274</b> JPYmn	<b>3,175</b> JPYmn	<b>3,108</b> JPYmn	<b>3,188</b> JPYmn	<b>3,235</b> JPYmn
(previous year)	(2,707 JPYmn)	(2,890 JPYmn)	(2,777 JPYmn)	(2,737 JPYmn)	(2,790 JPYmn)	(2,792 JPYmn)
No. of applicants of						
Doubutsu Kenkatsu	4,725	6,580	6,455	6,601	7,492	7,644
(gut microbiota testing)	(-)	(-)	(-)	(-)	(-)	(-)
(previous year)						
No. of samples for						
genetic testing	9,088	10,857	11,463	13,234	16,174	11,945
(previous year)	(-)	(-)	(-)	(-)	(-)	(-)

	October	November	December	January	February	March
Net premiums written*	<b>3,302</b> JPYmn	<b>3,230</b> JPYmn	<b>3,303</b> JPYmn	<b>3,430</b> JPYmn	JPYmn	JPYmn
(previous year)	(2,854 JPYmn)	(2,780 JPYmn)	(2,991 JPYmn)	(3,100 JPYmn)	(2,954 JPYmn)	(3,158 JPYmn)
No. of applicants of						
Doubutsu Kenkatsu	9,262	8,657	8,427	9,581		
(gut microbiota testing)	(-)	(-)	(857)	(5,256)	(4,926)	(5,146)
(previous year)						
No. of samples for						
genetic testing	13,399	15,703	13,140	14,729		
(previous year)	(-)	(-)	(-)	(517)	(2,014)	(5,211)


\*The impact of net premiums written from December 2019 was limited compared to the previous year. It is because one year has passed since the price increase following the product revision implemented in December 2018. However, the impact has been generally as expected.

(Reference) "Notice of the status of our activities" will be disclosed in the middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December and March.




## Net premiums written

No. of applicants of Doubutsu Kenkatsu (gut microbiota testing)



<sup>\*</sup>Started in December 2018

No. of samples for genetic testing



\*Started full-scale development in January 2019